This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Janssen Biotech, Inc.. Active years: 2019-2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2021
Title: Paul Imm: Innovator in Diabetes Treatment
Introduction
Paul Imm is a notable inventor based in Newtown, PA (US). He has made significant contributions to the field of diabetes treatment, holding 2 patents that focus on innovative methods for managing pre-type 1 diabetes.
Latest Patents
His latest patents include a method for treating pre-type 1 diabetes in a human subject. This invention relates to compositions and methods utilizing anti-TNF antibodies, specifically those with a heavy chain (HC) comprising SEQ ID NO:36 and a light chain (LC) comprising SEQ ID NO:37. These compositions are designed for use in the treatment or prevention of Type I Diabetes (T1D). Another patent focuses on anti-TNF antibodies, compositions, methods, and their use for the treatment or prevention of type 1 diabetes, reiterating the importance of these antibodies in managing this condition.
Career Highlights
Paul Imm is currently associated with Janssen Biotech, Inc., where he continues to develop innovative solutions in the medical field. His work is pivotal in advancing treatment options for individuals at risk of developing type 1 diabetes.
Collaborations
He collaborates with esteemed colleagues such as Joseph Hedrick and Elizabeth C Hsia, contributing to a dynamic research environment that fosters innovation.
Conclusion
Paul Imm's work exemplifies the impact of innovation in healthcare, particularly in the treatment of diabetes. His patents reflect a commitment to improving patient outcomes through scientific advancement.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile